Blood Purification Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

Blood Purification Devices Market by Product Type (Continuous Renal Replacement Therapy (CRRT) Device, Hemodialysis Device, Hemoperfusion Device, and Plasma Exchange Device), End-User (Hospitals, Dialysis Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to rising instances of various kidney diseases, surge in the cases of hypertension and diabetes leading to kidney disorders, and growing product development activities by the key players.

The blood purification devices market was valued at USD 17,734.52 million in 2024, growing at a CAGR of 5.40% during the forecast period from 2025 to 2032 to reach USD 26,864.87 million by 2032. The demand for the blood purification devices market is witnessing steady growth, driven by the rising instances of acute kidney injury (AKI) and chronic kidney disease (CKD), along with the increasing cases of hypertension and diabetes that contribute to kidney complications. Additionally, ongoing product development and the launch of advanced purification technologies by key players are enhancing treatment efficiency and patient outcomes. These are the combined factors that are creating a favorable landscape for sustained market expansion from 2025 to 2032.

Blood Purification Devices Market Dynamics:

As per data from the National Institutes of Health (2024), acute kidney injury (AKI) affects approximately 13.3 million people worldwide each year, with a significant portion of cases linked to infections, particularly in low- and lower-middle-income countries. This high global occurrence, especially in regions with limited access to advanced healthcare, is directly accelerating the market for blood purification devices. Since AKI often requires timely and effective extracorporeal blood purification to prevent life-threatening complications, the growing number of cases is driving demand for scalable, cost-effective, and clinically reliable treatment options. This need is prompting manufacturers to develop and distribute more adaptable purification technologies tailored to diverse healthcare environments. As a result, the increasing burden of AKI, particularly infection-induced cases, is playing a critical role in expanding the global blood purification devices market.

According to the National Institutes of Health (2022), CKD affects over 10% of the global population, more than 800 million individuals, particularly impacting older adults, women, racial minorities, and those with diabetes or hypertension. This large and growing patient population requires ongoing renal support, thereby increasing demand for blood purification technologies.

Additionally, data from the UK Kidney Association (2022) reported 683,136 instances of AKI in a single year, highlighting the urgent and widespread need for timely and effective interventions. Conditions like CKD and AKI often necessitate treatments such as hemodialysis and Continuous Renal Replacement Therapy (CRRT), driving the adoption of advanced blood purification devices. The scale and severity of these renal conditions are pushing healthcare systems to adopt more efficient, reliable, and accessible purification solutions, thereby propelling market growth.

Furthermore, an increase in product development activities among the key market players is escalating the market for blood purification devices. For example, in June 2024, Fresenius Medical Care (FME), a leading provider of kidney care products and services, started the second phase of bringing high-volume hemodiafiltration (HVHDF) therapy to the U.S. after receiving FDA 510(k) clearance for its updated 5008X CAREsystem. This new version included added features and marked an important step toward a wider U.S. launch later in the year, with full commercial rollout planned for 2026.

Driven by these compelling factors, the blood purification devices market is poised for substantial growth during the forecast period from 2025 to 2032.

However, the risk of complications & safety concerns associated with blood purification devices and the increasing number of product recalls, among others, are some of the key constraints that may limit the growth of the blood purification devices market.

Blood Purification Devices Market Segment Analysis:

Blood Purification Devices Market by Product Type (Continuous Renal Replacement Therapy (CRRT) Device, Hemodialysis Device, Hemoperfusion Device, and Plasma Exchange Device), End-User (Hospitals, Dialysis Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the blood purification devices market, the continuous renal replacement therapy (CRRT) device category is projected to account for the largest market share in 2024. This is driven by the primary factor that is rising cases of acute kidney injury (AKI), particularly among critically ill patients admitted to intensive care units (ICUs). CRRT is uniquely suited for these settings as it delivers a slower, more controlled, and continuous blood purification process, making it the preferred option for hemodynamically unstable patients who cannot tolerate the rapid fluid and solute shifts associated with conventional hemodialysis.

Also, the growing cases of life-threatening conditions such as sepsis and multi-organ failure, which frequently result in AKI, have further intensified the demand for CRRT systems. These clinical scenarios often require immediate and sustained renal support, positioning CRRT as an essential intervention in critical care.

Simultaneously, technological advancements have enhanced the functionality and ease of use of CRRT devices. Innovations such as automated fluid management, real-time monitoring, and intuitive user interfaces have improved therapeutic precision while reducing the operational burden on healthcare providers.

This expansion is further supported by regulatory milestones that reflect the growing versatility of CRRT platforms. For example, in August 2023, Quanta Dialysis Technologies(R) received FDA 510(k) clearance for expanded CRRT indications on its Quanta Dialysis System, highlighting the trend toward multifunctional and adaptable renal support devices.

Therefore, driven by these combined factors, the CRRT device category is anticipated to witness substantial growth, significantly contributing to the overall expansion of the blood purification devices market during the forecast period from 2025 to 2032.

North America is expected to dominate the overall blood purification devices market:

North America is projected to hold the largest share of the blood purification devices market in 2024, driven by several key factors. This regional dominance is largely driven by the high instances of chronic kidney disease CKD and its associated risk factors, including hypertension and diabetes. The region also benefits from a well-developed healthcare infrastructure, supportive reimbursement policies, and an increasing focus on advancing renal care. These factors collectively contribute to the widespread adoption of blood purification technologies, solidifying North America's position as a leading market throughout the forecast period.

According to the Centers for Disease Control and Prevention (CDC, 2024), over one in seven U.S. adults, approximately 35.5 million people, or 14 percent of the population, were affected by CKD. The condition disproportionately affected older adults, with a case rate of 34 percent in those aged 65 and above, compared to 12 percent among individuals aged 45 to 64, and 6 percent in the 18 to 44 age group. CKD is also slightly more common in women (14 percent) than in men (12 percent). Supporting this, the American Kidney Fund (2024) reported that around 808,000 individuals were living with kidney failure, with 135,000 new cases diagnosed in 2022, underscoring the escalating burden of kidney-related conditions in the country.

This growing and demographically diverse patient base is fueling demand for renal support therapies such as dialysis and continuous blood purification, particularly in hospitals, dialysis centers, and critical care settings.

Same source in 2025 stated that, in 2022, nearly half of U.S. adults that is 48.1% or roughly 119.9 million people, are affected by high blood pressure, defined as having a systolic reading over 130 mm Hg, a diastolic reading over 80 mm Hg, or currently taking medication to manage the condition. However, only about 1 in 4 adults with high blood pressure (22.5%, or 27 million people) have their condition under control. Additionally, in 2024 above source reported that approximately 38 million people were affected by diabetes.

Both hypertension and diabetes are major risk factors for the development of CKD and AKI, conditions that often require timely and effective blood purification treatments to manage fluid overload, toxin removal, and electrolyte imbalances. The growing burden of these chronic diseases is not only increasing the patient pool requiring renal support but also prompting healthcare providers to adopt advanced blood purification technologies. As a result, the escalating rates of hypertension and diabetes are directly contributing to the growth and expansion of the blood purification devices market.

Moreover, product development activities in the region are further expected to boost the market for blood purification devices. For instance, in July 2024, Tablo(R) is a groundbreaking, fully integrated mobile hemodialysis system developed by Outset Medical, a U.S.-based medical technology company, designed for the treatment of patients with both acute and chronic renal failure.

Together, these clinical, technological, and strategic drivers are expected to significantly propel the growth of the U.S. blood purification devices market throughout the forecast period from 2025 to 2032.

Blood Purification Devices Market Key Players:

Some of the key market players operating in the blood purification devices market include B. Braun Melsungen AG, Asahi Kasei Corporation, Fresenius SE and Co. KGaA, Baxter, Infomed SA, Jafron Biomedical Co., Ltd., Kaneka Corporation, Nikkiso Co., Ltd., SWS Medical Group, Medtronic, CytoSorbents Europe GmbH, Spectral Medical Inc., Haemonetics Corporation, Baihe Medical, ExThera Medical Corporation, and others.

Recent Developmental Activities in the Blood Purification Devices Market:

• In November 2024, Quanta Dialysis Technologies(R) received FDA 510(k) clearance for its Quanta Dialysis System to be used in home settings. With this approval, Quanta became the only company to offer a high dialysate flow system (500 mL/min) for end-stage renal disease (ESRD) patients across the full care continuum.
• In July 2024, the University of California, Los Angeles-led team developed a machine-learning model that accurately predicted the short-term survival of dialysis patients undergoing continuous renal replacement therapy (CRRT).
• In March 2024, Cerus Corporation, a U.S.-based company, reported positive topline results from its Phase III clinical trial evaluating a compound intended to be added to transfused blood to help prevent pathogens and reduce the risk of acute kidney injury.

Key takeaways from the blood purification devices market report study

• Market size analysis for current blood purification devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the blood purification devices market.
• Various opportunities available for the other competitors in the blood purification devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current blood purification devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the blood purification devices market growth in the future?

Target audience who can benefit from this blood purification devices market report study

• Blood purification devices product providers
• Research organizations and consulting companies
• Blood purification devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in blood purification devices
• Various end-users who want to know more about the blood purification devices market and the latest technological developments in the blood purification devices market.

Frequently Asked Questions for the Blood Purification Devices Market:

1. What are blood purification devices?

• Blood purification devices are medical systems designed to remove toxins, waste products, inflammatory mediators, or excess fluids from the blood, typically in patients with kidney failure, sepsis, autoimmune disorders, or other critical conditions. These devices operate using various techniques such as hemodialysis, hemofiltration, hemoperfusion, or plasmapheresis, and are commonly used in intensive care settings to support organ function and manage systemic imbalances.

2. What is the market for blood purification devices?

• The blood purification devices market was valued at USD 17,734.52 million in 2024, growing at a CAGR of 5.40% during the forecast period from 2025 to 2032 to reach USD 26,864.87 million by 2032.

3. What are the drivers for the blood purification devices market?

• The demand for the blood purification devices market is witnessing steady growth, driven by the rising instances of acute kidney injury (AKI) and chronic kidney disease (CKD), along with the increasing incidence of hypertension and diabetes that contribute to kidney complications. Additionally, ongoing product development and the launch of advanced purification technologies by key players are enhancing treatment efficiency and patient outcomes. These are the combined factors that are creating a favorable landscape for sustained market expansion from 2025 to 2032.

4. Who are the key players operating in the blood purification devices market?

• Some of the key market players operating in the blood purification devices market include B. Braun Melsungen AG, Asahi Kasei Corporation, Fresenius SE and Co. KGaA, Baxter, Infomed SA, Jafron Biomedical Co., Ltd., Kaneka Corporation, Nikkiso Co., Ltd., SWS Medical Group, Medtronic, CytoSorbents Europe GmbH, Spectral Medical Inc., Haemonetics Corporation, Baihe Medical, ExThera Medical Corporation, and others.

5. Which region has the highest share in the blood purification devices market?

• North America is projected to hold the largest share of the blood purification devices market in 2024, driven by several key factors. This regional dominance is largely driven by the high instances of chronic kidney disease CKD and its associated risk factors, including hypertension and diabetes. The region also benefits from a well-developed healthcare infrastructure, supportive reimbursement policies, and an increasing focus on advancing renal care. These factors collectively contribute to the widespread adoption of blood purification technologies, solidifying North America's position as a leading market throughout the forecast period.